ClassID:

97186

C07K16/286 - CPC Classification

Classification description:

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor

Recent Application in this class:
#1
20260097094
2026-04-09

METHODS FOR INHIBITING DIAZEPAM BINDING PROTEIN

#2
20250332291
2025-10-30

MONOCLONAL ANTIBODIES FOR TARGETING THE CARDIAC CONDUCTION SYSTEM

#3
20250313638
2025-10-09

MULTISPECIFIC BINDING AGENTS TARGETING DOPAMINE RECEPTOR D2 AND METHODS OF USE THEREOF

#4
20250297016
2025-09-25

ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF

#5
20250290153
2025-09-18

METHODS OF DIAGNOSING, DETERMINING THE PROGRESSION OF, AND TREATING A PROSTATE CANCER

#6
20250277040
2025-09-04

AGENT, USES AND METHODS FOR TREATMENT

#7
20250270330
2025-08-28

TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS

#8
20250263488
2025-08-21

METHODS AND SYSTEMS FOR IDENTIFYING OR TREATING CENTRAL NERVOUS SYSTEMS DISEASE

#9
20250250341
2025-08-07

CANNABINOID RECEPTOR TYPE 1 (CB1) BINDING PROTEINS AND USES THEREOF

#10
20250223365
2025-07-10

METHODS OF USE OF ANTI-SORTILIN ANTIBODIES

#11
20250206828
2025-06-26

ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES AND THE USE THEREOF

#12
20250197509
2025-06-19

ANTI-NMDA RECEPTOR ANTIBODIES AND METHODS OF USE

#13
20250145724
2025-05-08

Methods and Compositions Relating to Adenosine Receptors

#14
20250092144
2025-03-20

METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY

#15
20240409643
2024-12-12

ANTI-NMDAR2B ANTIBODIES, ANTIBODY-DRUG CONJUGATES, AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE

#16
20240409589
2024-12-12

MHC CLASS I EPITOPE DELIVERING POLYPEPTIDES

#17
20240360184
2024-10-31

DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS

#18
20240309097
2024-09-19

METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY

#19
20240245750
2024-07-25

METHODS FOR INHIBITING DIAZEPAM BINDING PROTEIN

#20
20240150472
2024-05-09

GENE CODING FOR CHIMERIC RECEPTOR FOR ANTI-ACETYLCHOLINE RECEPTOR AUTOANTIBODY

#21
20240132597
2024-04-25

METHODS OF USE OF ANTI-SORTILIN ANTIBODIES

#22
20240124594
2024-04-18

TREATMENT OF CVD AND SYSTEMIC SCEROSIS WITH BETA-1 ADRENERGIC RECEPTOR ANTIBODIES

#23
20240101681
2024-03-28

METHODS OF USE OF ANTI-SORTILIN ANTIBODIES

#24
20240069041
2024-02-29

METHODS FOR TREATING AND MONITORING FRONTOTEMPORAL DEMENTIA

#25
20240052041
2024-02-15

Therapeutic agent targeted to receptor protein, test agent, antibody that binds to receptor protein, and screening method for molecularly targeted drugs

#26
20230416365
2023-12-28

TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES

#27
20230374161
2023-11-23

COMPOSITIONS AND METHODS FOR INHIBITION OF NATURAL KILLER CELL RECEPTORS

#28
20230374143
2023-11-23

A SORTILIN ANTAGONIST FOR USE IN THE PREVENTION OR TREATMENT OF HEARING LOSS

#29
20230346940
2023-11-02

Method And System For Identifying And Validating Shared Candidate Antigens And Shared Antigen-Specific T Lymphocyte Pairs

#30
20230340132
2023-10-26

ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES

#31
20230242676
2023-08-03

POLYPEPTIDES, PROTEIN COMPLEXES AND METHOD FOR MAKING SAME

#32
20230183357
2023-06-15

ANTI-HUMAN NEUROTENSIN RECEPTOR 1 ANTIBODY AND USE THEREOF

#33
20230183335
2023-06-15

GLP1R AGONIST NMDAR ANTAGONIST CONJUGATES

#34
20230159643
2023-05-25

AGENT, USES AND METHODS FOR TREATMENT

#35
20230081477
2023-03-16

Therapeutic agent targeted to receptor protein, test agent, antibody that binds to receptor protein, and screening method for molecularly targeted drugs

#36
20230047941
2023-02-16

ANTI-SORTILIN ANTIBODIES AND METHODS OF USE THEREOF

#37
20220396620
2022-12-15

Cannabinoid receptor type 1 (CB1) antibodies, encoding nucleic acid molecules thereof and methods of use thereof

#38
20220348656
2022-11-03

Anti-sortilin antibodies and methods of use thereof

#39
20220313840
2022-10-06

LIGANDS TARGED TO EPIDERMAL GROWTH FACTOR RECEPTORS AND COMPOSITIONS FOR USE IN TREATING TUMORS

#40
20220306701
2022-09-29

MHC class I epitope delivering polypeptides

#41
20220298221
2022-09-22

CHIMERIC AUTOANTIBODY RECEPTOR (CAAR) THAT BINDS AUTOANTIBODIES TARGETING THE CENTRAL NERVOUS SYSTEM IN NEUROLOGICAL AUTOIMMUNE DISEASE

#42
20220275030
2022-09-01

De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals

#43
20220273751
2022-09-01

GPCR HETEROMER INHIBITORS AND USES THEREOF

#44
20220259319
2022-08-18

Methods and compositions relating to adenosine receptors

#45
20220251219
2022-08-11

METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY

#46
20220213198
2022-07-07

METHOD OF TREATMENT

#47
20220185899
2022-06-16

METHODS OF INCREASING PROGRANULIN LEVELS USING ANTI-SORTILIN ANTIBODIES

#48
20220185898
2022-06-16

METHODS OF USE OF ANTI-SORTILIN ANTIBODIES FOR TREATING A DISEASE, DISORDER, OR INJURY

#49
20220154292
2022-05-19

Methods of diagnosing, determining the progression of, and treating a prostate cancer

#50
20220154174
2022-05-19

Method of Selecting for Antibodies

#51
20220073611
2022-03-10

Anti-NMDA receptor antibodies and methods of use

#52
20220048995
2022-02-17

USE OF AN INHIBITOR OF NTSR1 ACTIVATION OR EXPRESSION FOR PREVENTING WEIGHT LOSS, MUSCLE LOSS, AND PROTEIN BLOOD LEVEL DECREASE IN SUBJECTS IN NEED THEREOF

#53
20210405011
2021-12-30

PHARMACEUTICAL FOR PREVENTING AND/OR TREATING STRESS LOAD-RELATED DISEASE

#54
20210292414
2021-09-23

AGENTS, USES AND METHODS FOR TREATMENT

#55
20210269524
2021-09-02

Agent, uses and methods for treatment

#56
20210268069
2021-09-02

GPCR HETEROMER INHIBITORS AND USES THEREOF

#57
20210259954
2021-08-26

CILIA-TARGETING NANOPARTICLES

#58
20210253648
2021-08-19

MHC class I epitope delivering polypeptides

#59
20210213118
2021-07-15

ANTIBODIES SPECIFIC FOR NTSR1 AND USES THEREOF

#60
20210198358
2021-07-01

Cannabinoid receptor type 1 (CB1) binding proteins and uses thereof

#61
20210179724
2021-06-17

VARIANT NUCLEIC ACID LIBRARIES FOR ADENOSINE RECEPTORS

#62
20210163591
2021-06-03

Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer

#63
20210040208
2021-02-11

Therapeutic agent targeted to receptor protein, test agent, antibody that binds to receptor protein, and screening method for molecularly targeted drugs

#64
20210023218
2021-01-28

Methods for promoting myelination and for treating demyelinating diseases

#65
20210017512
2021-01-21

CELL-TARGETING MOLECULES COMPRISING PROTEASE-CLEAVAGE RESISTANT, SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES AND CARBOXY-TERMINAL MOIETIES

#66
20200392229
2020-12-17

METHODS OF USE OF ANTI-SORTILIN ANTIBODIES

#67
20200360478
2020-11-19

GPCR heteromer inhibitors and uses thereof

#68
20200352950
2020-11-12

Novel method of treating dystonia

#69
20200308251
2020-10-01

Diagnosis and therapy of multiple sclerosis

#70
20200223928
2020-07-16

Isolated nucleic acids encoding anti-sortilin antibodies

#71
20200199234
2020-06-25

Tumor-targeted agonistic CD28 antigen binding molecules

#72
20200190188
2020-06-18

Agent, uses and methods for treatment

#73
20200024348
2020-01-23

Anti-Sortilin antibodies and methods of use thereof

#74
20200024347
2020-01-23

OR10H1 ANTIGEN BINDING PROTEINS AND USES THEREOF

#75
20190374565
2019-12-12

Methods of screening compounds useful for treatment of a liver disease

#76
20190263906
2019-08-29

IMMUNE MODULATORS FOR REDUCING IMMUNE-RESISTANCE IN MELANOMA AND OTHER PROLIFERATIVE DISEASES

#77
20190211066
2019-07-11

VACCINES FOR PREVENTING MENINGOCOCCAL INFECTIONS

#78
20190183976
2019-06-20

GPCR heteromer inhibitors and uses thereof

#79
20190153044
2019-05-23

MHC Class I Epitope Delivering Polypeptides

#80
20190127475
2019-05-02

Anti-sortilin antibodies and methods of use thereof

#81
20190085084
2019-03-21

Methods of increasing progranulin levels using anti-Sortilin antibodies

#82
20190062433
2019-02-28

Methods of use of anti-Sortilin antibodies for treating a disease, disorder, or injury

#83
20190023788
2019-01-24

Agents, uses and methods for treatment

#84
20180371082
2018-12-27

NOVEL ANTIBODY USEFUL IN NEUROLOGICAL OR NEURODEGENERATIVE DISORDERS

#85
20180355037
2018-12-13

Anti-human ADRB3 monoclonal antibody and application thereof in disease diagnosis and treatment

#86
20180305455
2018-10-25

Agent, uses and methods for treatment

#87
20180265586
2018-09-20

Anti-sortilin antibodies and methods of use thereof

#88
20180250322
2018-09-06

ANTIBODIES WHICH BIND TYPE I CANNABINOID RECEPTOR/ANGIOTENSIS II RECEPTOR HETEROMERS

#89
20180244802
2018-08-30

ANTIBODY OR ANTIBODY FRAGMENT OF NON-IG SCAFFOLD BINDING TO A BINDING REGION OF AN ANTI-N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTIBODY

#90
20180134788
2018-05-17

Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas

#91
20180119229
2018-05-03

Methods for detecting prostate cancer by determining the ratio of early to late endosomal markers

#92
20180092977
2018-04-05

NOVEL MONOCLONAL ANTIBODY INHIBITORS TARGETING POTASSIUM CHANNEL KCNK9

#93
20180037612
2018-02-08

VACCINES FOR PREVENTING MENINGOCOCCAL INFECTIONS

#94
20180030135
2018-02-01

HUMAN MONOCLONAL ANTIBODIES AGAINST OREXIN RECEPTOR TYPE 1

#95
20180002421
2018-01-04

Human monoclonal antibodies against orexin receptor type 1

#96
20170304384
2017-10-26

Substances and methods for the use in prevention and/or treatment in Huntington's disease

#97
20170267761
2017-09-21

Anti-sortilin antibodies, uses and methods for treatment

#98
20170240611
2017-08-24

Modulation of the VPS10p-Domain Receptor Family for the Treatment of Mental and Behavioural Disorders

#99
20170174763
2017-06-22

NOGO Receptor-Mediated Blockade of Axonal Growth

#100
20170158766
2017-06-08

Modulation of Activity of Neurotrophins

#101
20170153234
2017-06-01

Method for detecting GABAA receptor autoantibodies

#102
20170145098
2017-05-25

Anti-mGluR2 conformational single domain antibodies and uses thereof

#103
20170101636
2017-04-13

Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties

#104
20170096486
2017-04-06

AGENTS INHIBITING GRANULIN FOR TREATMENT OF CANCER

#105
20170052189
2017-02-23

METHOD FOR DIAGNOSING AND MONITORING THE PRESENCE OF CANCER IN A HUMAN SUBJECT

#106
20160376340
2016-12-29

Diagnosis and therapy of multiple sclerosis

#107
20160340394
2016-11-24

DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES FOR APPLICATIONS IN MAMMALS

#108
20160237138
2016-08-18

Nucleic acids encoding polypeptides which disrupt D1-D2 dopamine receptor coupling and modulate function

#109
20160200822
2016-07-14

Antibodies which bind type I cannabinoid receptor/angiotensin II receptor heteromers and methods of use

#110
20160177284
2016-06-23

CELL-TARGETED MOLECULES COMPRISING AMINO-TERMINUS PROXIMAL OR AMINO-TERMINAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS

#111
20160115230
2016-04-28

Antibody useful in neurological or neurodegenerative disorders

#112
20160068599
2016-03-10

METHOD FOR TREATING NEUROENDOCRINE CANCER

#113
20150376261
2015-12-31

Chimeric polypeptides comprising G protein-coupled receptors and VHH antibodies

#114
20150299654
2015-10-22

Lrp4/corin dopamine-producing neuron precursor cell marker

#115
20150239973
2015-08-27

Modulation of the Interaction Between SorLA and GDNF-Family Ligand Receptors

#116
20150050294
2015-02-19

Methods for diagnosing and treating neuroendocrine cancer

#117
20150050289
2015-02-19

Method of treating motor neuron disease with an antibody that agonizes MuSK

#118
20140370024
2014-12-18

Methods of treating pain by inhibition of VGF activity

#119
20140242087
2014-08-28

Modulation of the VPS10p-domain receptor family for the treatment of mental and behavioural disorders

#120
20140050730
2014-02-20

Methods for diagnosing and treating neuroendocrine cancer

#121
20130302352
2013-11-14

Methods for the prevention and/or treatment of memory impairment

#122
20130202600
2013-08-08

Methods for modulating D1-D2 dopamine receptor coupling and function

#123
20130171145
2013-07-04

Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers

#124
20130058939
2013-03-07

TREATMENT OF NEUROLOGICAL OR NEURODEGENERATIVE DISORDERS

#125
20120321624
2012-12-20

Targeting the neuromuscular junction for treatment

#126
20120270923
2012-10-25

Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer

#127
20120134991
2012-05-31

Polypeptides and methods for modulating D1-D2 dopamine receptor interaction and function

#128
20120100156
2012-04-26

Therapeutic Agent

#129
20120082671
2012-04-05

Modulation of activity of neurotrophins

#130
20120052075
2012-03-01

Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders

#131
20110229909
2011-09-22

RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies

#132
20110171205
2011-07-14

NOVEL 15571, 2465, 14266, 2882, 52871, 8203 AND 16852 MOLECULES AND USES THEREFOR

#133
20110166036
2011-07-07

Modulation of the Vps10p-domain for the treatment of cardiovascular disease

#134
20110097392
2011-04-28

ANTIBODY BOUND SYNTHETIC VESICLE CONTAINING MOLECULES FOR DELIVER TO CENTRAL AND PERIPHERAL NERVOUS SYSTEM CELLS

#135
20110014202
2011-01-20

Methods for diagnosing and treating neuroendocrine cancer

#136
20100303802
2010-12-02

Antibodies directed to mGluR7

#137
20100291102
2010-11-18

Therapeutic Agent

#138
20100278831
2010-11-04

Nogo receptor-mediated blockade of axonal growth

#139
20100260675
2010-10-14

Oxytocin Receptor Antagonists and Their Use for the Treatment of Pulmonary Related Diseases

#140
20100212029
2010-08-19

Assays utilizing nicotinic acetylcholine receptor subunits

#141
20100196376
2010-08-05

METHOD FOR REDUCING ALLERGEN-INDUCED AIRWAY HYPERRESPONSIVENESS

#142
20100028356
2010-02-04

METHOD OF DIAGNOSING A NEURODEGENERATIVE DISEASE

#143
20090324588
2009-12-31

Antibodies to the alpha-7 nicotinic receptors and methods of treating inflammatory disorders with the same

#144
20090317382
2009-12-24

Use of effector-function-deficient antibodies for treatment of auto-immune diseases

#145
20090269786
2009-10-29

RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies

#146
20090234102
2009-09-17

Hepatitis C virus inhibitors

#147
20090226450
2009-09-10

Novel 15571, 2465, 14266, 2882, 52871, 8203 and 16852 molecules and uses therefor

#148
20090181026
2009-07-16

Tomoregulin-2-antibody compositions and methods for the diagnosis and treatment of Alzheimer's disease

#149
20080219984
2008-09-11

Nogo receptor-mediated blockade of axonal growth

#150
20080199437
2008-08-21

Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers

#151
20080027020
2008-01-31

Human Neuropeptide Receptor

#152
20070281306
2007-12-06

Novel 15571, 2465, 14266, 2882, 52871, 8203 and 16852 molecules and uses therefor

#153
20070264195
2007-11-15

Modulation of activity of neurotrophins

#154
20070156813
2007-07-05

Method and apparatus for collaborative system

#155
20060147914
2006-07-06

Method of screening for agents that modulate a homer signaling pathway

#156
20060088913
2006-04-27

Mutation associated with epilepsy

#157
20060035283
2006-02-16

Neuroprotective therapeutics preventing ERK/MAPK activation through the NMDA receptor

#158
20060025334
2006-02-02

Vanilloid receptor-2 ligands for treating anxiety or depression

#159
20060013809
2006-01-19

Immunotoxin derived from a recombinant human autoantibody and method of using thereof

#160
20050266010
2005-12-01

Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders

#161
20050163773
2005-07-28

Methods and pharmaceutical compositions for dopaminergic modulation of t-cell adhesion and activity

#162
20050124795
2005-06-09

Human 5-HT3-C protein

#163
20050003998
2005-01-06

Therapeutic use of selective LXR modulators

#164
17935261
2024-02-20

Methods for weight reduction

#165
16262600
2020-06-16

Methods for treating cancer using GRM8 inhibitors

#166
14966614
2019-03-19

Multi-functional particles and methods of using the same